NCT01420328View on ClinicalTrials.gov

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2011

Primary Completion Date

July 1, 2015

Study Completion Date

July 1, 2016

Conditions
Inflammation
Interventions
DRUG

Vytorin

Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks

DRUG

Placebo

Placebo treatment for 6 weeks

Trial Locations (1)

14209

Diabetes Endocrinology Center of WNY, Buffalo

Sponsors

Collaborators (1)

Kaleida Health
All Listed Sponsors
collaborator

Kaleida Health

OTHER

lead

University at Buffalo

OTHER

NCT01420328 - To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects | Biotech Hunter | Biotech Hunter